Please use this identifier to cite or link to this item: http://theses.ncl.ac.uk/jspui/handle/10443/2957
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStephens, Peter Andrew-
dc.date.accessioned2016-06-15T13:23:08Z-
dc.date.available2016-06-15T13:23:08Z-
dc.date.issued2015-
dc.identifier.urihttp://hdl.handle.net/10443/2957-
dc.descriptionPhD Thesisen_US
dc.description.abstractThe aim of this work was to characterise the checkpoint 1 kinase (CHK1) inhibitor V158411; its effect on DNA damage-induced checkpoint function in parallel with chemo/radio-potentiation in a panel of cell lines characterised for their CHK1 expression and activity. Furthermore, to determine the single agent cytotoxicity in a panel of cell lines; to identify potential pharmacodynamic biomarkers of CHK1 activity suitable for measuring the activity of inhibitors in the clinic; and to explore the role of p53 and identify other potential determinants of sensitivity to CHK1 inhibitors. V158411 on its own reliably reduces CHK1serine296 phosphorylation and gemcitabine-mediated induction of CHK1serine296 phosphorylation. Single agent V158411 reduces the fraction of cancer cells in G2 of the cell cycle and abrogates cisplatin and IR-mediated increases in the proportion of cells in G2. V158411 shows significant single agent activity in a number of cell lines. There was significant potentiation of ionising radiation with V158411. There was no significant chemopotentiation of either gemcitabine or cisplatin with coadministration with V158411. p53 status was not associated with significant differences in sensitivity to single agent V158411, chemo or radiosensitisation. However, loss of DNA-PKcs or the presence of a DNA-PKcs inhibitor conferred resistance to V158411. CHK1 and DNA-PKcs mRNA levels were found to be elevated in tumour samples compared to normal tissue levels. The LC50 of V158411 was shown to correlate with the inducible (2 Gy IR) phosphorylation of DNA-PKcsserine2096 in a panel of cancer cells.en_US
dc.description.sponsorshipSir Bobby Robson Foundation for funding my post as a Clinical Research Associate and in particular the trustees for their investment in me.en_US
dc.language.isoenen_US
dc.publisherNewcastle Universityen_US
dc.titleAn evaluation of the checkpoint kinase inhibitor V158411en_US
dc.typeThesisen_US
Appears in Collections:Northern Institute for Cancer Research

Files in This Item:
File Description SizeFormat 
Stephens, P. 2015.pdfThesis9.27 MBAdobe PDFView/Open
dspacelicence.pdfLicence43.82 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.